Advertisement


Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Welcome and Introduction to Vi3C

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Advertisement